Objective. To evaluate the prevalence of atypical antipsychotic use in privately insured children and the diagnoses associated with treatment. Study design. Claims were used to conduct a retrospective cohort study of children aged 2 through 18 years in the Midwest, covered by private insurance between 2002 and 2005 (n = 172 766). The 1-year prevalence of children receiving atypical antipsychotics was determined along with associated diagnoses. Results. The 1-year prevalence of atypical antipsychotics ranged from 7.9 per 1000 in 2002 to 9.0 in 2005. The leading diagnoses were disruptive behavior disorders (67%), mood disorders (65%), and anxiety disorders (43%). The authors found that 75% of children on atypical antipsychotics had more than one psychiatric diagnosis. Conclusions. Atypical antipsychotic use is primarily seen in children who have multiple psychiatric diagnoses. Studies are needed to assess the long-term safety and effectiveness in such patients with multiple diagnoses.
Introduction
Between 1995 and 2002, a 5-fold increase in antipsychotic use in children and adolescents occurred in the United States, largely because of increases in the use of atypical antipsychotic medications. 1 In 2001, as many as 14.9 per 1000 Medicaid-enrolled children were using atypical antipsychotics, despite the fact that these medications were not FDA approved for pediatric patients. 2 Although studies have found evidence of significant side effects in children, including weight gain, hyperlipidemia, hyperprolactinemia, extrapyramidal complications, potential cardiac arrythmias, and most recently, transient ischemic attacks, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] evidence suggests that atypical antipsychotics may be effective in the treatment of behavior disorders, schizophrenia, and bipolar disorders. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Given this evidence, risperidone received FDA approval for the treatment of irritability associated with autism in October 2006 and for schizophrenia or bipolar disorder in August 2007. 24, 25 Given this evidence, risperidone received FDA approval for the treatment of irritability associated with autism in October 2006 and schizophrenia and bipolar disorder in August 2007 along with aripiprazole in February 2008.
Cooper et al 1 examined antipsychotic medication usage in Medicaid-insured youths and found that 53% of new users were being treated for behavioral or mood disorders. Similarly, in a population of children in a public mental health system, Patel et al 26 found disruptive behavior disorders to be the leading diagnoses associated with antipsychotic treatment along with depressive and bipolar disorders. It is unclear if similar prescribing practices occur in privately insured populations. 2, 27 We evaluated the prevalence of atypical antipsychotic use in privately insured children and the diagnoses associated with treatment. from a large private insurance company in a moderately sized Midwestern state. Inclusion criteria were (1) age 2 to 18 years and (2) simultaneous pharmacy and medical coverage continuously for more than 1 year. All dosage forms for aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone were included in the analysis using individual National Drug Codes (Cerner Multum, Denver, CO).
We defined the 1-year prevalence of atypical antipsychotics as the number of children with at least 1 prescription for a specified medication during each year of the study period. Individuals who received more than 1 antipsychotic during a single year contributed a single case to the prevalence.
Diagnostic codes were assigned by practitioners using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Grouping of diagnoses was as follows: disruptive/aggressive behavior, mood, anxiety, psychotic, developmental (including autism), and other mental disorders (see appendix). Other mental disorders included diagnoses such as tic disorders, Tourette's syndrome, and dependent and nondependent drug use. An individual may have had more than 1 psychiatric diagnosis during the entire study period and contributed 1 case under each diagnostic category, as appropriate.
Analyses using SAS version 9.1 (SAS Institute, Cary, NC) included descriptive statistics and c 2 tests for bivariate analyses. Subanalyses included evaluation of the use of antipsychotic medications across gender and age. The association between antipsychotic medication use and diagnostic category was computed using odds ratios. Differences were considered statistically significant at a 2-sided P < .05 level.
Approval for human subjects research and a waiver of informed consent were received by the institutional review board at Saint Louis University.
Results
The study population included 172 766 children with a mean age of 10.4 (standard deviation [SD] = 4.9) years. Of these, 51% (88 159) were boys. A total of 2194 individual children received at least 1 prescription for an atypical antipsychotic during the entire study period. In all, 64% of children receiving atypical antipsychotics (1404) were male, and the mean age was 12.6 (SD 3.8) years.
The 1-year prevalence of antipsychotic use was 7.9 per 1000 in 2002 (total enrolled n = 73 894), 8.1 per 1000 in 2003 (n = 84 323), 8.6 per 1000 in 2004 (n = 94 832), and 9.0 per 1000 in 2005 (n = 99 467). In 2005, the prevalence was lower in girls (6.2 per 1000) than boys (11.6 per 1000), with boys being 1.9 times more likely to receive an atypical antipsychotic than girls (95% confidence interval [CI] = 1.6, 2.2; P < .001). Children 10 years of age and older were 2.3 times more likely to be prescribed atypical antipsychotics than children younger than 10 (95% CI = 2.0, 2.6; P < .001).
Across the entire study period, disruptive disorders, including attention deficit/hyperactivity disorder (ADHD), were the most common diagnoses, except in the oldest age group ( Table 1) . The most common single ICD-9-CM diagnosis was ADHD, found in 1242 children or 57% of all the children receiving atypical antipsychotics. The most common psychiatric diagnoses categorized as "other" were tic disorders and dependent and nondependent drug use (ICD-9-CM 304 and 305). A total of 141 children (6.4%) on atypical antipsychotics had no psychiatric diagnosis coded during the study period.
We found that 75% of the 2194 children on antipsychotics had more than one psychiatric diagnosis during the study period ( Figure 1 ). The leading combinations were a disruptive behavior and a mood disorder (258, 12%) and a disruptive disorder, a mood disorder, and an anxiety disorder (175, 8%). Children with multiple diagnoses coded during the study period were 9.7 times more likely to be prescribed atypical antipsychotics than children with a single psychiatric diagnosis (95% CI = 8.7, 10.9; P < .001).
Boys on atypical antipsychotics were 2.6 times more likely than girls to have a diagnosis of disruptive disorder (95% CI = 2.1, 3.1; P < .001) and 1.7 times more likely to have a diagnosis of developmental delay (95% CI = 1.3, 2.2; P < .001). Girls were 1.6 times more likely to have a diagnosis of mood disorder (95% CI = 1.4, 2.0; P < .001) and 1.5 times more likely to have a diagnosis of anxiety disorder (95% CI = 1.3, 1.8; P < .001). Regardless of the diagnosis, older children were more likely to be prescribed antipsychotics than children 2 to 4 years of age (Table 2) .
Risperidone was the most commonly prescribed atypical antipsychotic medication (1170 children, 53%) followed by quetiapine fumarate (720 children, 33%). Other atypical antipsychotics included olanzapine (471 children), aripiprazole (434 children), ziprasidone (197 children), and clozapine (2 children).
Discussion
In privately insured children and adolescents, the prevalence of atypical antipsychotics was 9.0 per 1000 in 2005. Boys were almost 2 times more likely to receive atypical antipsychotics than girls. Most important, the leading diagnoses among children on antipsychotics were disruptive behavior disorders (67%). In addition, our study is the first to describe the multiple psychiatric diagnoses found in most children (75%) on atypical ant ipsychotics. In fact, these children were almost 10 times more likely to be on an atypical antipsychotic than children with a single psychiatric diagnosis.
The 2005 prevalence of atypical antipsychotic use in our study was higher than the 2001 prevalence of 2.67 per 1000 identified in a previously published study of privately insured youth across the United States 27 and lower than the published prevalence of 13.1 per 1000 in 2001 in a Midwest Medicaid population. 2 The differences in prevalence are probably because of variability in study populations, as evidenced by studies that have found dramatically lower rates of use in the United Kingdom, for example. 28 Previous studies have found that privately insured youth have consistently lower psychotropic prevalence than Medicaid-insured youth 2,29 ; our study findings suggest that this continues to be the case. Our findings suggest a persistent trend in the use of atypical antipsychotics in privately insured youth and may explain the higher prevalence in our privately insured population. Finally, the differences in prevalence may reflect variability in prescribing practices by region of the country as a result of state policies and/or mental health care access, although previous studies have found no such variation. 30, 31 We found that disruptive behavior disorders were the leading diagnoses (67%) associated with the use of atypical antipsychotics, similar to previous studies. Cooper et al 32 found that 43% of children on atypical antipsychotics were diagnosed with ADHD or conduct disorder, whereas Patel et al 26 in the use of antipsychotics for behavior disorders; our findings suggest that this trend has continued. In addition, our findings are similar to a study assessing US trends in antipsychotic use, which found that 53% of new users received prescriptions for behavioral indications. 1 Harrison-Woolrych et al 11 surveyed physicians about the indications for treatment and confirmed disruptive disorders to be the leading indication for atypical antipsychotic use. 11 Although previous studies have shown that there is increasing use of multiple psychotropic drugs in children, [34] [35] [36] this is the first study to identify the high rate of multiple psychiatric diagnoses in children on atypical antipsychotics. Zito et al 37 found that 41% of youth in foster care covered by Medicaid insurance received ≥3 different classes of drugs (primarily antidepressants, ADHD drugs, and antipsychotic agents). 37 This has been found even in very young children. 38 Although a series of Figure 1 . Total number of psychiatric diagnoses coded during the study period in children prescribed atypical antipsychotics studies have examined the safety of certain concomitant psychotropic drugs (primarily methylphenidates and selective serotonin reuptake inhibitors), only one included atypical antipsychotics. 20, [39] [40] [41] [42] [43] [44] Although atypical antipsychotics appear to be a promising source of treatment for children with conduct disorders, 9, 44, 45 many studies that have been conducted in children focused on children with developmental delays such as autism. 7, 21, 44, [46] [47] [48] [49] [50] [51] Of note, only 14% of our population on atypical antipsychotics had a diagnosis of developmental delays, including autism, mental retardation, and learning disabilities. Almost half of these children were prescribed atypical antipsychotics other than risperidone, the most extensively studied of the atypical antipsychotics at the time of the study. Our finding that 75% of children prescribed atypical antipsychotics were diagnosed with multiple psychiatric conditions indicates that rigorously controlled longterm studies in children with multiple disorders beyond disruptive behavior and/or developmental delay are needed to guide treatment. 46 The present analysis has some limitations. Prescribing rates may not be generalizable to the entire population because this is a retrospective analysis of prescription and diagnosis claims from a private payer health plan. We only looked at atypical antipsychotics; however, by 2002 atypical antipsychotics made up more than 92% of antipsychotics prescribed nationally. 2, 33 Billing diagnoses were used rather than standardized diagnostic assessments. The diagnostic criteria used by practitioners to code a particular diagnosis were not controlled; however, the codes are likely to reflect the physician's perception of the diagnoses prompting treatment. Practitioners are limited as to the number of diagnoses they may code for a single visit. Therefore, we collapsed codes over the study period to obtain a total clinical picture for a single participant. We did not link dates of diagnostic codes to prescriptions. Given the potentially transient nature of certain psychiatric diagnoses, this may not be accurate. In addition, children who were enrolled for the entire study period may have contributed to the individual prevalence for more than 1 year. Finally, our analysis did not capture any prescriptions filled outside of the pharmacy plan, nor did it assess drug compliance.
Conclusions
The prevalence of atypical antipsychotics in privately insured children (9.0 per 1000 in 2005) is substantial, and although less than the prevalence in Medicaid populations, now this group ranks as one of the most commonly prescribed to youth and is frequently being prescribed in children with multiple psychiatric diagnoses. Safety and effectiveness studies in such children are necessary given the high rate of use in this population. 
